Teva meets profit expectations but misses on revenue
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA TASE: TEVA) nowadays documented $3.7 billion profits for the initial quarter of 2022, down 8% from the corresponding quarter of 2021, and somewhat beneath the analysts’ consensus of $3.75 billion. Non-GAAP earnings per share was $.55, meeting the analysts’ forecast.

Teva cut its 2022 income forecast from $15.6-16.2 billion to $15.4-16 billion and its Copaxone profits forecast from $850 million to $750 million.




Related Content













In response, Teva’s share price tag is down 2.58% in premarket trading on the NYSE.

Teva president and CEO Kare Schultz stated, We are happy to carry on resolving opioid-related litigations with the latest settlements in Florida and Rhode Island together with the provision of lifesaving opioid treatment plans and recovery medicines for those who require them.”

He continued: “Though easing of Covid-19 connected restrictions has led to good momentum in our European small business, we are seeing fluctuations of overseas exchange premiums, and have hence lowered our 2022 earnings outlook, whilst reaffirming our earnings and money stream guidance.”

Revealed by Globes, Israel business enterprise news – en.globes.co.il – on Could 3, 2022.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2022.